Teva's Huntington drug launch on hold after FDA rejection | Fierce Biotech
Loss of Orai2-Mediated Capacitative Ca2+ Entry Is Neuroprotective in Acute Ischemic Stroke | Stroke
JCM | Free Full-Text | Thinking Outside the Ischemia Box: Advancements in the Use of Multiple Sclerosis Drugs in Ischemic Stroke
Teva charged by U.S. in generic drugs price-fixing probe - Philadelphia Business Journal
Teva Blood Pressure Medication – Eunice Kennedy Shriver Center
Nasal delivery gets antibody to rodent brains to treat stroke
Pharmaceutics | Free Full-Text | Advances in Antibody-Based Therapeutics for Cerebral Ischemia
Teva at the Top of Generics - The Israel High Tech & Investment ...
FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes
FDA Receives Resubmission of the Apixaban Drug Application to Reduce Stroke in Patients With Atrial Fibrillation | DAIC
Teva recalls 2 lots of hypertension drug on dissolution issues
Teva Launches Honestly HD Website to Provide People Living With Huntington's Disease (HD) Information, Inspiration and Resources on HD Chorea
Transitioning Teva revamps branding to emphasize brand-generic unity | Fierce Pharma
Clinical, Neuroimaging, and Genetic Markers in Cerebral Amyloid Angiopathy-Related Inflammation: A Systematic Review and Meta-Analysis | Stroke
Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke | Stroke
Acute Ischemic Stroke Therapeutics Market: Growth Opportunities led by Athersys Inc. and Bayer AG - Technavio
Multimodal Predictive Modeling of Endovascular Treatment Outcome for Acute Ischemic Stroke Using Machine-Learning | Stroke
Teva recalls one lot of IDArubicin Hydrochloride Injection USP
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Neurology
Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma
Frontiers | Microglia-mediated neuroinflammation and neuroplasticity after stroke
2020 Pharma Choice Multichannel Gold Winner Intouch Group and Teva | PM360
A risk model for prediction of diagnosis of cancer after ischemic stroke | Scientific Reports
Outcomes Among Patients With Reversible Cerebral Vasoconstriction Syndrome: A Nationwide United States Analysis | Stroke
NORO-Neurology Osteopathic Residency Organization | Department of Neurology & Ophthalmology
Teva wins FDA nod for sublingual film to treat opioid dependence - Drug Delivery Business
